Member Info for Kjn2

Downside imo is maybe 10% if no deal, and deal could be 25-30% from here imo. The question is if large holders would be happy with 1150-1200p as bid level if that was on the table. Looking at the LT share price chart I could see some being ok selling at those levels.

Systematic shorts are momentum driven: price goes up and they short (some of them). They are terrible at M&A situations.

I think the spread here is very decent. Think odds of closing high imo.

Disclosed shorts have covered substantially.

Let’s see if the Sky or betaville fellows dig out more over the weekend.

The idiot clown is back. The clown who gets Spire and every special situation wrong. Run guys, run. What an idiot.

The opportunity here is that earnings could grow strongly going into next year, accretion is the crux here for buyers. Large caps prefer bolt on deals over large risky deals in medtech. And AMS is a stable grower at high margins with barely any net debt and a very low valuation imo. Great setup.

My guess only a US large cap is coming over the top of HB and may pay 315p per share. Let’s see.

Been discussing with other retail investors a list of potential bidders. AMS is at such a low valuation, the deal makes sense for any surgical care company that has enough cash at hand. Need some synergies and not antitrust risk:

- Stryker

- Integra

- BD

- Medtronic

- Teleflex

- Terumo

Feel free to add your thoughts. Some of them have decent synergies.

That’s very good news, also gives other interested parties time to enter the bidding process.

Those aren’t large buys at all. If someone bought 1% of company that’s different, but couple hundred k shares is nothing.

Let’s see if betaville or Sky are faster with news than an RNS. Let’s go.

Always use prices of exchanges and not intermediaries.

Time for a large cap US medtech company to come in with a 315p bid. Best guess.

Kenal you clown, everyone on here laughs about you as you got Spire completely wrong. You are the running joke here, time to read investing for dummies.

Fyi, HB’s share price is completely irrelevant as it is a cash offer.

Wasn’t it betaville that reported 285p? Imo HB wouldn’t have known that that’s only the starting point.

I guess likes of Stryker, BD, JnJ, Integra etc could all easily pay 300+ and still have an accretive deal. IMO this isn’t a done deal yet.

Launching a sale process after 4+ approaches is usually the norm would say.

All the large medtech / surgical care companies have internal M&A departments, they may look at AMS as we speak. 300p is easy for many of them.

Would be helpful if larger shareholders pushed for a sale process. 285p implies ev/ebitda of 7.5x for 2027, when all the synergies and cost savings kick in.

Larger US companies could look at this and say this could be a very accretive deal even at 300p.

No, it’s standard language. It’s not a binding offer yet. Boilerplate language.

Anyone attending the AGM today? Why doesn’t the Board launch a proper sale process now? Stock was 350ish only in 2022. Shareholder returns should be on the agenda today…

I think there could be a positive surprise. AMS earnings expected rise materially (consensus) in the next 1-2 years and some of their product in surgical care have great potential in the US. A Stryker, BD or Integra could potentially be all interested. Any large buyer with plenty of cash can buy AMS at a low multiple and have a nice accretion.

BTW: Anyone who understands activism in the US cannot take the activist seriously.

That’s wrong, also sell side saying break price around 780-800 or so. Obviously there is downside.

Maybe other surgical care corporates are evaluating bids now? 285p seems low imo given all the synergies and efficiencies kicking in by next year.

There could be larger US companies that just plug AMS in and distribute their products.

Let’s see, doubt it’s over yet imo best guess.